BowFlex Inc. : Good timing to aim a technical rebound
Entry price | Target | Stop-loss | Potential |
---|
$17.01 |
$0 |
$15.75 |
-100% |
---|
Nautilus’ share price was heavily penalized and is now in an oversold situation near to a solid support area.
From a fundamental viewpoint, the company has a value in line with the industry as its enterprise value ratios show.
Moreover, EPS estimates for the two coming years have been recently revised upward by analysts. This positive fact opens the way for a better appreciation of the security by investors.
The stock is now coming back close to a rising trend line and a support in daily data. 50-week moving average is supporting the stock and technical indicators illustrate the oversold situation. The USD 16.25 area could cause a positive reaction for the coming trading sessions and allow a technical rebound towards the USD 19.3 mid-term resistance.
The trading strategy can benefit from the proximity of the strong support currently tested in order to buy Nautilus with a good timing. The potential gain is 13.3%. Investors might place a stop loss order at USD 15.7 in order to avoid important losses.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.